Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. approved a set of updated Rules of Procedure for the Strategy Committee on 26 November 2025. According to these revised guidelines, the Strategy Committee will be composed of more than three directors appointed by the board, ensuring a dedicated chairman to convene and oversee meetings.
The updated rules clarify the Committee’s responsibilities, including reviewing the company’s medium-to-long-term development strategy, assessing asset transactions, and monitoring major capital operations. Proposals on corporate bonds, mergers, and innovations in new markets also fall under its scope. In addition, the Committee holds the authority to supervise the execution of relevant board resolutions and may seek professional advice in performing its duties.
The guidelines stipulate clear procedures for meetings, such as requiring majority approval for decisions, managing conflicts of interest through abstentions, and maintaining thorough records of all deliberations. The Committee will disclose its annual performance report concurrently with the company’s annual results and will publish its terms of reference according to applicable listing rules. The revised document becomes effective upon board approval and aligns with prevailing national laws, regulatory requirements, and the listing rules for the company’s shares.
Comments